Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197723 · ClinicalTrials.gov registry record
Study of How People Make Decisions About Prostate Cancer Risk
A clinical trial of BRCA1/2 and Geneitic Testing, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT07197723 is a study of BRCA1/2 and Geneitic Testing that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07197723, a study of BRCA1/2 and Geneitic Testing, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Conditions Studied
Interventions
- OTHER Assessments
- GENETIC cheek (buccal) swab
- OTHER optional collection of blood
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2027-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07197723
The ClinicalTrials.gov registry entry for NCT07197723 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with BRCA1/2 appearing as the primary indexed condition, and to 3 interventions - of which Assessments is the first listed.
NCT07197723 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07197723 about?
NCT07197723 is a clinical study titled "Study of How People Make Decisions About Prostate Cancer Risk". The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to lea...
What is the current status of trial NCT07197723?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-09-25. Estimated completion is 2027-09.
What conditions does trial NCT07197723 study?
This clinical trial studies the following conditions: BRCA1/2, Geneitic Testing.
What interventions are being tested in trial NCT07197723?
The interventions under investigation include: Assessments (OTHER), cheek (buccal) swab (GENETIC), optional collection of blood (OTHER).
Who is sponsoring clinical trial NCT07197723?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197723 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1/2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.